Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma : Current Status and Challenges

Show full item record



Permalink

http://hdl.handle.net/10138/329391

Citation

Almangush , A , Leivo , I & Makitie , A A 2021 , ' Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma : Current Status and Challenges ' , Frontiers in oncology , vol. 11 , 616629 . https://doi.org/10.3389/fonc.2021.616629

Title: Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma : Current Status and Challenges
Author: Almangush, Alhadi; Leivo, Ilmo; Makitie, Antti A.
Contributor organization: HUS Head and Neck Center
University Management
Doctoral Programme in Clinical Research
Doctoral Programme in Oral Sciences
Clinicum
Department of Ophthalmology and Otorhinolaryngology
Date: 2021-03-08
Language: eng
Number of pages: 5
Belongs to series: Frontiers in oncology
ISSN: 2234-943X
DOI: https://doi.org/10.3389/fonc.2021.616629
URI: http://hdl.handle.net/10138/329391
Abstract: Oral squamous cell carcinoma (OSCC) forms a major health problem in many countries. For several decades the management of OSCC consisted of surgery with or without radiotherapy or chemoradiotherapy. Aiming to increase survival rate, recent research has underlined the significance of harnessing the immune response in treatment of many cancers. The promising finding of checkpoint inhibitors as a weapon for targeting metastatic melanoma was a key event in the development of immunotherapy. Furthermore, clinical trials have recently proven inhibitor of PD-1 for treatment of recurrent/metastatic head and neck cancer. However, some challenges (including patient selection) are presented in the era of immunotherapy. In this mini-review we discuss the emergence of immunotherapy for OSCC and the recently introduced biomarkers of this therapeutic strategy. Immune biomarkers and their prognostic perspectives for selecting patients who may benefit from immunotherapy are addressed. In addition, possible use of such biomarkers to assess the response to this new treatment modality of OSCC will also be discussed.
Subject: oral squamous cell carcinoma
immunotherapy
biomarkers
immune response
survival
3122 Cancers
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
fonc_11_616629.pdf 257.6Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record